{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:32:23Z","timestamp":1793892743178,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s13760-026-03181-y","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:41:38Z","timestamp":1788788498000},"page":"2063-2077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of anti-CD20 monoclonal antibodies versus teriflunomide in relapsing multiple sclerosis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5574-0810","authenticated-orcid":false,"given":"Hafiz Muhammad","family":"Haris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Asad","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gul Sher","family":"Ghouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Maqsood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Zaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Laiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishmail","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Waleed Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakeena","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Umair Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Faqeer","family":"Hussain Bokhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"3181_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL et al (2008) B-Cell Depletion with Rituximab in Relapsing\u2013Remitting Multiple Sclerosis. N Engl J Med 358:676\u2013688. https:\/\/doi.org\/10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"key":"3181_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","volume":"52","author":"SL Hauser","year":"2006","unstructured":"Hauser SL, Oksenberg JR (2006) The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration. Neuron 52:61\u201376. https:\/\/doi.org\/10.1016\/j.neuron.2006.09.011","journal-title":"Neuron"},{"key":"3181_CR3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L et al (2020) Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler J 26:1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","journal-title":"Mult Scler J"},{"key":"3181_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G et al (2020) Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol 77:1132\u20131140. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568","journal-title":"JAMA Neurol"},{"key":"3181_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 376:221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"key":"3181_CR6","doi-asserted-by":"publisher","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","volume":"90","author":"A Bar-Or","year":"2018","unstructured":"Bar-Or A, Grove RA, Austin DJ et al (2018) Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. Neurology 90:e1805\u2013e1814. https:\/\/doi.org\/10.1212\/WNL.0000000000005516","journal-title":"Neurology"},{"key":"3181_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA et al (2018) Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 90:777\u2013788. https:\/\/doi.org\/10.1212\/WNL.0000000000005347","journal-title":"Neurology"},{"key":"3181_CR8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C et al (2011) Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. N Engl J Med 365:1293\u20131303. https:\/\/doi.org\/10.1056\/NEJMoa1014656","journal-title":"N Engl J Med"},{"key":"3181_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G et al (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13:247\u2013256. https:\/\/doi.org\/10.1016\/S1474-4422(13)70308-9","journal-title":"Lancet Neurol"},{"key":"3181_CR10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F (2018) Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurol 75:320\u2013327. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4011","journal-title":"JAMA Neurol"},{"key":"3181_CR11","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane Handbook for Systematic Reviews of Interventions, 1st edn. Wiley. https:\/\/doi.org\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"3181_CR12","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"3181_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"3181_CR14","unstructured":"RoB 2: a revised tool for assessing risk of bias in randomised trials | The BMJ. Accessed: April 26 (2026) https:\/\/www.bmj.com\/content\/366\/bmj.l4898"},{"key":"3181_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188 10.1016\/0197\u20132456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"3181_CR16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung H-P et al (2022) Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med 387:704\u2013714. https:\/\/doi.org\/10.1056\/NEJMoa2201904","journal-title":"N Engl J Med"},{"key":"3181_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA et al (2020) Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 383:546\u2013557. https:\/\/doi.org\/10.1056\/NEJMoa1917246","journal-title":"N Engl J Med"},{"key":"3181_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00415-025-13221-x","volume":"272","author":"A Cagol","year":"2025","unstructured":"Cagol A, Schaedelin S, Ocampo-Pineda M et al (2025) Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort. J Neurol 272:491. https:\/\/doi.org\/10.1007\/s00415-025-13221-x","journal-title":"J Neurol"},{"key":"3181_CR19","doi-asserted-by":"publisher","unstructured":"Boyko AN, Alifirova VM, Lukashevich IG et al (2023) [Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4\/MIRANTIBUS], vol 123. Zh Nevrol Psikhiatr Im S S Korsakova, pp 43\u201352. https:\/\/doi.org\/10.17116\/jnevro202312307243","DOI":"10.17116\/jnevro202312307243"},{"key":"3181_CR20","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002. https:\/\/doi.org\/10.1136\/bmj.d4002","journal-title":"BMJ"},{"key":"3181_CR21","doi-asserted-by":"publisher","first-page":"104002","DOI":"10.1016\/j.msard.2022.104002","volume":"65","author":"H Mukhtar","year":"2022","unstructured":"Mukhtar H, Yasmeen U, Siddiqa S, Sarfraz Z, Sarfraz A (2022) Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis. Mult Scler Relat Disord 65:104002. https:\/\/doi.org\/10.1016\/j.msard.2022.104002","journal-title":"Mult Scler Relat Disord"},{"key":"3181_CR22","doi-asserted-by":"publisher","first-page":"106668","DOI":"10.1016\/j.msard.2025.106668","volume":"103","author":"I Mohammadi","year":"2025","unstructured":"Mohammadi I, Rajai Firouzabadi S, Aghajanian S et al (2025) Efficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord 103:106668. https:\/\/doi.org\/10.1016\/j.msard.2025.106668","journal-title":"Mult Scler Relat Disord"},{"key":"3181_CR23","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40263-022-00961-x","volume":"36","author":"X Wu","year":"2022","unstructured":"Wu X, Tan X, Zhang J et al (2022) The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis. CNS Drugs 36:1155\u20131170. https:\/\/doi.org\/10.1007\/s40263-022-00961-x","journal-title":"CNS Drugs"},{"key":"3181_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","volume":"84","author":"AK Carlson","year":"2024","unstructured":"Carlson AK, Amin M, Cohen JA (2024) Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. Drugs 84:285\u2013304. https:\/\/doi.org\/10.1007\/s40265-024-02011-w","journal-title":"Drugs"},{"key":"3181_CR25","doi-asserted-by":"publisher","unstructured":"Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA (2023) Is it ethical to use teriflunomide as an active comparator in phase 3 trials? Mult Scler Relat Disord. 78:104911. https:\/\/doi.org\/10.1016\/j.msard.2023.104911","DOI":"10.1016\/j.msard.2023.104911"},{"key":"3181_CR26","doi-asserted-by":"publisher","unstructured":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies: Expert Opinion on Drug Safety: Vol 0, No 0 - Get Access. Accessed: May 16, 2026. https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/14740338.2025.2574668","DOI":"10.1080\/14740338.2025.2574668"},{"key":"3181_CR27","doi-asserted-by":"publisher","first-page":"101476","DOI":"10.1016\/j.lanepe.2025.101476","volume":"59","author":"A Cagol","year":"2025","unstructured":"Cagol A, Schaedelin S, Pretzsch R, Kappos L, Sormani MP, Granziera C (2025) The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis. Lancet Reg Health - Eur 59:101476. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101476","journal-title":"Lancet Reg Health - Eur"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03181-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03181-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03181-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:51:10Z","timestamp":1793890270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03181-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["3181"],"URL":"https:\/\/doi.org\/10.1007\/s13760-026-03181-y","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval <b>and patient consent<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}]}}